Document:

Exhibit 10.54

 

Term
Sheet for Providing License, Services and Collaboration

Prepared and Signed in Tel-Aviv on March
5, 2012

 

Between:

 

XTL Biopharmaceuticals Ltd.

Domiciled at 85 Medinat Hayehudim Street,
Herzliya Pituach, 46766

(Hereinafter: "the Company")

As the First Party;

 

And:

 

Clalit Health Services

Domiciled at 101 Arlozorov Street, Tel-Aviv

(Hereinafter: "Clalit")

As the Second Party;

 

And:

 

Mor Research Application Ltd.

Domiciled at 38 Habarzel Street, Tel-Aviv,
69710

(Hereinafter: "Mor")

As the Third Party;

 

		Whereas:	Clalit Research Institute (hereinafter: "the
Institute"), which acts under Mor, is performing scientific studies for Clalit based, among others, on the analysis of
data stored in Clalit's databases (hereinafter: "the Databases");

 

		Whereas:	Mor serves as Clalit's commercial channel and has the
technologies and scientific knowledge in the biotechnology, pharma and diagnostics fields;

 

		Whereas:	The Company is a pharmaceutical company listed for trade
on the Tel-Aviv Stock Exchange which develops drugs for various diseases;

 

		Whereas:	The Parties are interested in strategically collaborating
in producing and analyzing data (hereinafter: "the Data") and in producing scientific reports based on these
Data (hereinafter: "the Contents") from the Databases pertaining only to the technologies originating from Clalit's
inventions and patents that are commercialized by Mor (hereinafter: "Clalit's Technologies");

 

    	1

    	 

    

 

Whereby it was Agreed, Declared and
Conditioned between the Parties as follows:

 

		1.	General

 

		1.1	The preamble and appendices to this Agreement form an integral part thereof.

 

		1.2	The Parties hereby represent and warrant that the contents of this contract reflect all the issues
agreed upon and conditioned between them in full and that the Parties will not be bound by any assurances, publications, representations,
presentations, implications and verbal and/or written undertakings that are not included in this Agreement and that have been reached
prior to its signing, if any.

 

		1.3	The section headlines have been drafted merely for the convenience of the Parties; they do not
form part of the Agreement nor are they to be used for interpreting the Agreement.

 

		1.4	Any change to the contract and any agreement, understanding, presentation, waiver and extension
will be performed in advance and in writing.

 

		2.	License terms

 

		2.1	Clalit hereby grants the Company the right to receive from the Institute the Contents based on
Data from the Clalit's Databases in connection with Clalit's Technologies for projects whose contents will be agreed upon between
the Parties in advance and in writing (hereinafter: "the Project(s)"). Any agreement regarding the Contents of
a certain Project or Projects which describes the nature and objective of the Project, the type of services to be rendered by the
Institute, the manpower needed for the Project, schedules, liability and insurance and the consideration payable by the Company
to the Institute for the Project (as detailed below) will be attached to this Agreement as an appendix.

 

		2.2	In cases in which the Contents required for the Project cannot be obtained within a reasonable
timeframe for a scientific, business, operational or legal reason, the Institute will be entitled to refuse to perform the Project(s)
and the Company shall not have any argument or claim against the Institute and/or Mor in this respect. Without derogating from
the general nature of the aforesaid, if the Company and the Institute fail to reach agreement regarding the Contents of a certain
Project, the Project will not be carried out and the Company shall have no argument or claim in this respect.

 

		3.	The consideration

 

In return for the usage right
underlying this Agreement, the Company will pay the Institute the cost basis of producing and analyzing the Data and producing
the scientific reports based on the Data analysis (the Contents) as above, as estimated by the Institute and as specified in the
relevant Project appendix, plus 10% royalties calculated according to the amount of royalties to which Mor is entitled pursuant
to its agreement with the Company regarding Clalit's Technologies commercialized by Mor and that are paid in addition to the royalties
payable by the Company to Mor.

 

    	2

    	 

    

 

		4.	Non-exclusivity

 

		4.1	This Agreement does not grant the Company any rights, unless expressly stated otherwise herein.

 

		4.2	The Company is aware that the engagement underlying this Agreement represents a term sheet engagement
only and that the Institute is not obligated to perform a specific number of Projects (if at all) and the Company hereby waives
any argument or claim in this respect.

 

		4.3	The Company is also aware that the engagement underlying this Agreement does not grant the Company
a right to any exclusivity and does not limit, confine or prevent the Institute from operating in any area of activity at its discretion.

 

		4.4	Notwithstanding the aforementioned in this section 4, the Institute will not be allowed to make
any commercial use of the Contents of the Projects agreed upon between the Institute and the Company and for which the consideration
has been paid, as detailed in section 3 above. For the removal of doubt, this subsection 4.4 does not impair the Institute's right
to use the Data underlying the Contents mentioned in this subsection 4.4 without any restriction.

 

		5.	The Parties' representations and warranties

 

		5.1	Clalit hereby represents and warrants that it has guided the Institute to engage in analyzing the
Databases for the purpose of producing data and insights and to promote Clalit's strategic objectives and has allowed it to do
so under the limitations of applicable laws.

 

		5.2	Clalit and Mor hereby represent and warrant that to the best of their knowledge, there is no legal
and/or factual and/or other impediment which prevents them from entering into this Agreement under its current conditions and from
meeting all their obligations thereunder.

 

		5.3	The Company hereby represents and warrants that there is no legal and/or factual and/or other impediment
which prevents it from entering into this Agreement under its current conditions and from meeting all its obligations thereunder.

 

		6.	Confidentiality and Databases

 

The Company, including its
employees and anyone engaged on its behalf, hereby undertakes to maintain in complete confidentiality any data or information which
reaches it as a result of and/or in connection with this Agreement, not to transfer it to any other party and not to use it other
than for the purpose of meeting its obligations pursuant to this Agreement, both during the Agreement period and thereafter for
an indefinite period. The Company will guarantee the fulfillment of this undertaking by its employees and anyone engaged on its
behalf. The Company undertakes to sign a letter of liability on its behalf in respect of the Company's, the managers' and the employees'
duty to maintain the confidentiality of the information made available to them as customary for Clalit, see Appendix A
hereby attached.

 

    	3

    	 

    

 

		7.	Employer-employee relations

 

The Parties hereby represent
and warrant that this Agreement creates a contractor-customer relationship between them only and that they will have no partnership,
trust or employer-employee relations whatsoever.

 

		8.	Agreement term and termination

 

Each party will be entitled
to terminate this Agreement at any time by providing the counterparties a written notice one hundred and eighty (180) days in advance.
The Parties will conclude Projects whose performance has begun prior to the termination of the Agreement under the relevant terms.

 

		9.	Miscellaneous

 

		9.1	The Parties will sign additional documents as reasonably required for the adoption and performance
of this Agreement.

 

		9.2	The Company may not assign and/or transfer this Agreement, in whole or in part, or any benefit
granted thereby, to another, whether with or without consideration, unless it has obtained Clalit's advance written consent.

 

		9.3	The agreement of any of the Parties to deviate from any condition mentioned herein, either in a
specific case or in a series of cases, will not represent a precedent and will not have the same bearing on other cases in the
future.

 

		9.4	If either of the Parties fails to enforce or late enforces a certain right of the rights conferred
to it pursuant to this Agreement and/or applicable laws, either in a specific case or in a series of cases, will not be viewed
as waiver of said right or of any other rights.

 

		9.5	Notices regarding this Agreement will be delivered by registered mail or to the Parties' domiciles
as stated in the preamble to this Agreement (or to any other domicile as notified in writing) and any such notice will be viewed
as if it has been delivered to the addressee at the elapse of three (3) business days from the date of delivery via registered
mail.

 

		9.6	Each Party shall bear any applicable tax payment in connection with this Agreement pursuant to
the law.

 

		9.7	The court residing in Tel-Aviv-Jaffa or in the central district shall have the exclusive local
jurisdiction to discuss any matters relating to or resulting from this Agreement and the Parties hereby waive their right to apply
to any other court not residing in Tel-Aviv-Jaffa or in the central district in advance.

 

    	4

    	 

    

 

In Witness whereof, the
Parties hereby provide their Signatures as mentioned above:

 

	/s/ David Grossman, Ronen Twito	 	/s/ Michal Ofer
	XTL Biopharmaceuticals Ltd.	 	Clalit Health Services

 

	/s/ Pinhas Ben-Elazar
	Mor Research Application Ltd.

  

    	5Exhibit 10.55

SHARE PURCHASE AGREEMENT

 

THIS SHARE PURCHASE
AGREEMENT (the “Agreement”) dated March 14, 2012 by and among XTL Biopharmaceuticals Ltd., a public company
incorporated under the laws of the State of Israel (the “Company”) and the subscriber detailed on the 2nd
Signatory Page herein (the "Investor").

 

WITNESSETH:

 

  WHEREAS,
the Company is a biopharmaceutical company focused on the development, in-licensing, acquisition, and commercialization of proprietary
products and late-stage pharmaceutical product candidates for the treatment of unmet medical needs; and

 

  WHEREAS,
the Company's shares are traded on the Tel-Aviv Stock Exchange ("TASE") and Company's ADRs are quoted on the Pink
Sheets; and

 

  WHEREAS,
the Board of Directors of the Company has decided to raise funds by way of a private placement on TASE of an amount between US$3
Million and US$3.5 Million by way of the issuance to investors of Units (as defined below) on the terms and conditions detailed
in Exhibit A attached hereto (the "Private Placement"); and

 

  WHEREAS,
the Investor desire to invest in the Company pursuant to the terms and conditions set forth in the Private Placement and this Agreement;
and

 

  NOW,
THEREFORE, in the consideration of the mutual promises and covenants set forth herein, the parties agree as follows:

 

		1.	Issue and Purchase of the Units

 

1.1         Purchase of
Units. At the Closing (as defined below), subject to the terms and conditions hereof, the Company shall issue and allot to
the Investors, and the Investors shall purchase from the Company such number of Units as set out in the 2nd Signatory
Page attached hereto (the “Issued Securities”), in consideration of the payment by the Investors to the Company
upon the Closing of the Investment Amount set out in the 2nd Signatory Page attached hereto (the “Investment”).

 

1.2         Units.
Each "Unit" shall comprise of (i) six (6) Ordinary Shares, nominal value NIS 0.1 each of the Company (the "Ordinary
Shares"), (ii) two (2) non tradable warrants (no. 1) ("Warrants No.1") and (iii) one (1) non tradable
warrant (no. 2) ("Warrant No. 2"). The terms and conditions of Warrant No. 1 and Warrant No. 2 are set out in
Exhibit A attached hereto.

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

1.3         Private
Placement. The Private Placement shall be performed in accordance with the Israeli Securities Regulations (Private Offering
of Securities in a Listed Company), 5760-20001 (the "Security Regulations") in accordance with a Private Placement
Report published by the Company immediately after the signing and execution of this Agreement.

 

2.           Closing
of the Private Placement

 

2.1. The Closing.
The issue and allotment of the Issued Securities and the purchase of the Issued Securities by the Investors shall take place at
a closing (the “Closing”), to be held at the offices of Kantor & Co., Oz House, 14 Abba Hillel Rd., Ramat
Gan, Israel subject to the terms and conditions of this Agreement, immediately upon fulfillment of the Closing Conditions (as defined
below) detailed below (the "Closing Date").

 

2.2. Transactions
at Closing. At the Closing, the following transactions shall occur, which transactions shall be deemed to take place simultaneously
and no transactions shall be deemed to have been completed or any document delivered until all such transactions have been completed
and all required documents delivered:

 

2.2.1. The Company
shall deposit with the registration company a share certificates evidencing the Ordinary Shares included in the Issued Securities
acquired by the Investors with instructions to transfer such Ordinary Shares to respective account designated by each Investor;

 

2.2.2. The Investor
shall deliver to the Company the bank account number opened in the Investor's name with an Israeli broker who is a member of TASE
to which the Ordinary Shares detailed in Section 2.2.1 above will be deposited by the registration company.

 

2.2.3. The Company
shall deliver to the Investor a duly signed and executed Warrant Certificate in relation to the Warrant No. 1 included in the Issued
Securities acquired by the Investor hereunder;

 

2.2.4. The Company
shall deliver to the Investor a duly signed and executed Warrant Certificate in relation to the Warrant No. 2 included in the Issued
Securities acquired by the Investor hereunder;

 

2.2.5. The Investor
shall cause the transfer to the Company of the Investment Amount for the Issued Securities being issued hereunder, by wire transfer,
banker's check, or such other form of payment as is mutually agreed by the Company and the Investors.

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

3.         Representations
and Warranties of the Investor

 

The Investor hereby
represents and warrants to the Company as follows:

 

3.1. This Agreement,
when executed and delivered by it, will constitute a valid, binding, and enforceable obligation. The execution, delivery, and performance
of its obligations hereunder have been duly authorized by all necessary corporate or partnership action.

 

3.2. The Investor
is an experienced investor The Investor represents and agrees that the Issued Securities are purchased only for investment, for
its own account. The Investor understands and acknowledges that the Warrant No. 1 and Warrant No. 2 have not been registered under
the Israeli securities laws of any jurisdiction.

 

3.3. The Investor
understands and acknowledges that it has been advised to rely on their own professional tax advisors with regard to its investment
pursuant to this Agreement.

 

3.4. The Investor
understands and acknowledges that the Company constitutes a “high-risk” investment due to the fact that the Company
is in the business of developing pharmaceutical product candidates for the treatment of unmet medical
needs, and that there is no assurance as to any return on such Investor’s investment pursuant to this Agreement.

 

3.5. The Investor
represents and acknowledges that such Investor is aware of the restrictions on sale of any of the Issued Securities acquired by
it under the Private Placement as imposed by Section 15C of the Israeli Securities Law, 5728-1968 (the and any regulations promulgated
thereunder.

 

4.         Conditions
Precedent

 

Conditions to Closing
by the Investors. The obligations of the Investors to purchase the Issued Securities and to transfer the Investment Amount
is subject to the final approval of the board of directors of Company and the approval of TASE to register for trade the Ordinary
Shares and the Ordinary Shares underlying the Warrants of the Issued Securities in accordance with the Securities Regulations.

 

5.         Affirmative
Covenants

 

The Ordinary Shares
included in the Issued Securities acquired by the Investors shall have all the rights and privileges attached to the Ordinary Shares
of the Company as set forth in the Company’s existing Articles of Association.

 

6.         Miscellaneous.

 

6.1. Further Assurances.
Each of the parties hereto shall perform such further acts and execute such further documents as may reasonably be necessary to
carry out and give full effect to the provisions of this agreement and the intentions of the parties as reflected thereby.

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

6.2. Governing
Law. This Agreement shall be governed by and construed according to the laws of the State of Israel, without regard to the
conflict of laws provision thereof, and the parties hereto irrevocably submit to the exclusive jurisdiction of the courts in Tel-Aviv,
Israel in respect of any dispute or matter arising out of or connected with this Agreement.

 

6.3. Successors
and Assigns. Except as otherwise expressly stated to the contrary herein, the provisions hereof shall inure to the benefit
of, and be binding upon, the successors, assigns under law, heirs, executors, and administrators of the parties hereto. None of
the rights, privileges or obligations of the Investor set forth in, arising under, or created by this Agreement may be assigned
or transferred without the prior written consent of the Company.

 

6.4. Entire Agreement;
Amendment and Waiver.

 

This Agreement and
the Schedules hereto constitute the full and entire understanding and agreement between the parties with regard to the subject
matters hereof and thereof. All prior understandings and agreements among the Parties are void and of no further effect. Any term
of this Agreement may be amended, waived, or discharged (either prospectively or retroactively, and either generally or in a particular
instance), by a written instrument signed by all the Parties to this Agreement.

 

6.5. Notices, etc.

 

All notices and other
communications required or permitted hereunder to be given to a party to this Agreement shall be in writing and shall be telecopied
or mailed by registered or certified mail, postage prepaid, or otherwise delivered by hand or by messenger, addressed to such party’s
address as set forth in Schedule 6.5 attached hereto or at such other address as the party shall have furnished to each
other party in writing as above provided. Any notice sent in accordance with this Section 6.5 shall be effective (i) if mailed
by registered or certified mail, five (5) business days after mailing, (ii) if sent by messenger, upon delivery, and (iii) if send
via telecopier, upon transmission and telephonic confirmation of receipt or (if transmitted and received on a non-business day)
on the first business day following transmission and telephonic confirmation of receipt, or upon receipt of a copy sent by mail
as set forth above.

 

6.6. Delays or
Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party upon any breach or default under
this Agreement, shall be deemed a waiver of any other breach or default therefore or thereafter occurring. Any waiver, permit,
consent, or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver
on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the
extent specifically set forth in such writing. All remedies, either under this Agreement, or by law, or otherwise afforded to any
of the parties, shall be cumulative and not alternative.

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

6.7. Severability.
If any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable under applicable law, then
such provision shall be excluded from this Agreement and the remainder of this Agreement shall be interpreted as if such provision
were so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Agreement shall
be interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and
intention of the excluded provision as determined by such court of competent jurisdiction.

 

6.8. Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original and enforceable against
the parties actually executing such counterpart, and all of which together shall constitute one and the same instrument.

 

6.9. Heading, Preamble,
and Schedules. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. The Preamble and Schedules are an integral and inseparable part of this Agreement.

 

    IN WITNESS WHEREOF
the parties have signed this Agreement as of the date first hereinabove set forth.

 

(Intentionally left Blank) 

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

IN WITNESS WHEREOF the parties have signed
this Agreement as of the date first hereinabove set forth.

 

THE COMPANY:

 

	XTL BIOPHARMACEUTICALS LTD.	 
	 	 	 
	By:	/s/ David Grossman, Ronen Twito	 
	Name:	David Grossman, Ronen Twito	 
	Title:	CEO, CFO	 

 

(1st Signatory Page of
Share Purchase Agreement)

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

IN WITNESS WHEREOF the parties have signed
this Agreement as of the date first hereinabove set forth.

 

THE INVESTOR:

 

MUST INTERNATIONAL TRADING LIMITED LTD.

 

	By:	/s/Hila Fisher	 
	Name:	Hila Fisher on behlf of Simon Doyev	 
	Title:	Owner	 

 

	Number of Units Acquired	 	Investment Amount	 	Account Details
	 	 	 	 	 	 
	 	 	US$	1,000,000	 	 

 

*) Minimum of ~$US100,000 (NIS 380,000)

 

(2nd Signatory Page of
Share Purchase Agreement)

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

IN WITNESS WHEREOF the parties have signed
this Agreement as of the date first hereinabove set forth.

 

THE INVESTOR:

 

TALMA GINZBURG INVESTMENT LTD.

 

	By:	/s/ Tal Ginzburg	 
	Name:	 	 
	Title:	 	 

 

 

	Number of Units Acquired	 	Investment Amount	 	Account Details
	 	 	 	 	 	 
	31,500	 	NIS	 149,184	 	 

 

*) Minimum of ~$US100,000 (NIS 380,000)

 

(2nd Signatory Page of
Share Purchase Agreement)

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

IN WITNESS WHEREOF the parties have signed
this Agreement as of the date first hereinabove set forth.

 

THE INVESTOR:

 

MENORA MIVTAHIM UNDERWRITERS & MANAGEMENT
LTD.

 

	By:	/s/ Gil Kalderon	 
	Name:	Gil Kalderon	 
	Title:	Managing Director	 

 

	Number of Units Acquired	 	Investment Amount	 	Account Details
	 	 	 	 	 	 
	105,575	 	NIS	 500,000	 	 

 

*) Minimum of ~$US100,000 (NIS 380,000)

 

(2nd Signatory Page of
Share Purchase Agreement)

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

IN WITNESS WHEREOF the parties have signed
this Agreement as of the date first hereinabove set forth.

 

THE INVESTOR:

 

DROR TAMARI

 

	By:	/s/ Dror Tamari	 
	Name:	Dror Tamari	 
	Title:	 	 

 

	Number of Units Acquired	 	Investment Amount	 	Account Details
	 	 	 	 	 	 
	120,000	 	NIS	 568,320	 	 

 

*) Minimum of ~$US100,000 (NIS 380,000)

 

(2nd Signatory Page of
Share Purchase Agreement)

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

IN WITNESS WHEREOF the parties have signed
this Agreement as of the date first hereinabove set forth.

 

THE INVESTOR:

 

PROVIDENT FUND OF THE EMPLOYEES OF THE HEBREW
UNIVERSITY OF JERUSALEM LTD.

 

	By:	/s/ Shmuel Rosenblum	 
	Name:	Shmuel Rosenblum	 
	Title:	CEO	 

 

	Number of Units Acquired	 	Investment Amount	 	Account Details
	 	 	 	 	 	 
	73,900	 	NIS	 349,990	 	 

 

*) Minimum of ~$US100,000 (NIS 380,000)

 

(2nd Signatory Page of
Share Purchase Agreement)

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

IN WITNESS WHEREOF the parties have signed
this Agreement as of the date first hereinabove set forth.

 

THE INVESTOR:

 

BANK JULIUS BAER & CO. LTD.

 

	By:	/s/ U. Mettler, S. Siebenmann	 
	Name:	U. Mettler, S. Siebenmann	 
	Title:	 	 

 

	Number of Units Acquired	 	Investment Amount	 	Account Details
	 	 	 	 	 	 
	800,000	 	USD	1,012,322	 	 

 

*) Minimum of ~$US100,000 (NIS 380,000)

 

(2nd Signatory Page of
Share Purchase Agreement)

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

EXHIBIT A

 

	Unit:	Each Unit consists of:	6 Ordinary Shares of XTL; and
	 	 	2 Warrants (No. 1); and
	 	 	1 Warrants (No. 2).

 

		Unit Price:	NIS 4.736 Based on the Average Price on TASE for the
last 14 days, calculated as of the date of this letter (NIS 0.7894 multiplied by 6)

 

		Warrants 1:	Exercise period of six (6) months from the date of grant
for an exercise price of NIS 0.95 per share (linked to the $US) Warrant (No.1) shall not be registered for trading.

 

		Warrants 2:	Exercise period of thirty six (36) month from the date
of grant for an, exercise price of NIS 1.02 per share (linked to the $US) Warrant (No. 2) shall not be registered for trading.

 

		Lock-up:	The securities issued in such private placement shall
be locked up in accordance with the rules and regulations of the Israeli Securities Laws.

 

*) if the average share price on the
transaction completion date will be higher than NIS 0.94, the warrants exercise price shall be negotiated.

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

 

    	 

    	 

    

 

Dear Investors,

 

According to Exhibit A to the Share Purchase
Agreement dated March 14, 2012 signed by you (the “Agreement”), and due to the fact that the average share price
for the 14 days prior to the completion of the transaction according to the Agreement is higher than NIS 0.94, the warrants exercise
price is herby adjusted to reflect the updated share price by keeping the same ratios as in the Agreement, as follows:

 

		Warrants 1:	Exercise period of six (6) months from the date of grant
for an exercise price of NIS 1.046 per share (linked to the $US) Warrant (No.1) shall not be registered for trading.

 

		Warrants 2:	Exercise period of thirty six (36) month from the date
of grant for an, exercise price of NIS 1.124 per share (linked to the $US) Warrant (No. 2) shall not be registered for trading.

  

	 	 	Warrant #1	 	 	Warrant #2	 
	Adjustment calculation	 	NIS	 
	Exercise price according to the Agreement	 	 	0.950	 	 	 	1.020	 
	Premium rate as of the date the Agreement was sent	 	 	6.03	%	 	 	13.84	%
	Share price as of the date of XTL's board resolution	 	 	0.987	 	 	 	 	 
	Final adjusted exercise price	 	 	1.046	 	 	 	1.124	 

 

THE INVESTOR:

 

	By:	 
	Name:	 
	Title:	 

 

XTL Biopharmaceuticals LTD. - Ordinary
Share Purchase Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}]]